NIH supports later-stage research and development for previously funded small business Phase II projects, bridging the gap to commercialization.
Funder: National Institutes of Health
Due Dates: January 5, 2027 (Application) | April 5, 2027 (Application) | September 5, 2027 (Application) | January 5, 2028 (Application) | April 5, 2028 (Application) | September 5, 2028 (Application) | January 5, 2029 (Application) | April 5, 2029 (Final application)
Funding Amounts: Up to $30 million total for up to 4 years, subject to component-specific limits; 100% matching funds required
Summary: Supports later-stage R&D by previous NIH SBIR/STTR Phase II recipients to bridge the gap to commercialization.
Key Information: Only U.S. small businesses with a previous NIH Phase II award may apply, within six due dates after that award’s budget period expires.
NIH’s Phase IIB Strategic Breakthrough award provides follow-on research and development support for small businesses moving previously funded NIH SBIR or STTR Phase II projects toward commercialization. The R44 program addresses the funding gap that can persist after Phase II, particularly for biomedical technologies requiring regulatory approval, complex manufacturing methods, or development for small markets.
Projects must contribute to the mission of a participating NIH institute or center. NIH emphasizes strong commercial potential: the likelihood that the technology will become an effective, successful product. Applications may include clinical trials, although projects aligned only with NCATS or ORIP cannot propose trials under this opportunity. Applicants are strongly encouraged to discuss project fit and budgets with program staff before applying.